Lupus
47
15
16
18
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.5%
4 terminated out of 47 trials
81.8%
-4.7% vs benchmark
2%
1 trials in Phase 3/4
22%
4 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (47)
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Patient-Centered Assessment of Symptoms and Outcomes
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
The BRIDGE Pain Study
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
JBT-101 in Systemic Lupus Erythematosus (SLE)
Deployment o the Multidisciplinary Prospective Cohort Imminent
Direct to Patient Minimal Risk Biospecimen and Data Collection Research
Complete Cognitive Intervention for cSLE
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Cardiac Imaging in Systemic Disorders: the ORACLES Registry
The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)
Safety and Efficacy of ONT01 in Lupus
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)